Skip to main content
OpenTrials
Completed

NCT Number: NCT05183022

Total30 Sphere Contact Lenses

The purpose of this study is to map comfort over the full wear day in established, asymptomatic, soft CL wearers who are refit in Total30 Sphere CLs.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Alabama at Birmingham, Birmingham, Alabama, United States

Loading trial locations.

About this study

Contact lens (CL) wearers frequently face eye discomfort symptoms, especially towards the end of the wear day. This burdensome discomfort can unfortunately cause patients to remove their CLs before their desired wear time. While comfortable wear times vary from patient to patient, Terry et al. has suggested that patients should be able to comfortably wear their CLs for at least 12 hours per day for at least 6 days per week. Nevertheless, the literature currently lacks sufficient data to comment fully on the full day wear experience, which for many patients may be 16 or more hours per day, especially if they have demanding careers. One CL that has the potential to allow for all day comfort is the Total30 Sphere CLs, which is a new water gradient, monthly CL aimed at delivering all day comfort and visual performance. Thus, the purpose of this study is to map comfort over the full wear day in established, asymptomatic, soft CL wearers who are refit in Total30 Sphere CLs. These data are not only important for judging the performance of Total30 Sphere CLs, but they will provide some of the first insights into the full day CL wearing experience over one month.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Current contact lens wearers who have 20/20 visual acuity or better
  • Minimally symptomatic as based upon Contact Lens Dry Eye Questionnaire scores (≤10)
  • Astigmatism better than or equal to 0.50 D in each eye
  • Must have regularly worn 2 week or monthly contact lenses within the past 6 months
  • Must provide a glasses prescription that is is less than 3 years old
  • Willing to start wearing their contact lenses between 6:00 AM and 8:00 AM and wear their contact lenses until 11:00 PM each day

Exclusion criteria

  • Past or Current hard CL use
  • Any known systemic health conditions that are thought to alter tear film physiology
  • History of viral eye disease
  • History of ocular surgery
  • History of severe ocular trauma
  • Active ocular infection or inflammation
  • Currently using isotretinoin-derivatives
  • Currently using ocular medications
  • Currently using rewetting drops or artificial tear
  • Pregnant or breast feeding

Treatment and study plan

Total30 Sphere Contact Lenses

Device

Participants will be refit into Total30 Sphere contact lenses and followed for 1 month.

Other names: Lehfilcon A

Primary outcomes

  1. Visual Analog Scale (VAS) Ocular Comfort

    Time frame: 1 month

    A visual analog scale (VAS) was used to compare end of day ocular comfort at 16 hours of contact lens wear over the 1 month study (0 to 100 scale with 100 being best).

Sponsors and collaborators

Lead sponsor

University of Alabama at Birmingham

Other

Collaborators

  • Alcon Research

Registry information

Official study title

Do Total 30 Sphere Contact Lenses Provide a Comfortable Wearing Experience All Day?

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Jan 10, 2022
Registry last updated
Dec 16, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.